Fecal microbiota transplantation in metabolic syndrome: History, present and future

P. F. de Groot, M. N. Frissen, N. C. de Clercq, M. Nieuwdorp*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

The history of fecal microbiota transplantation (FMT) dates back even to ancient China. Recently, scientific studies have been looking into FMT as a promising treatment of various diseases, while in the process teaching us about the interaction between the human host and its resident microbial communities. Current research focuses mainly on Clostridium difficile infections, however interest is rising in other areas such as inflammatory bowel disease (IBD) and the metabolic syndrome. With regard to the latter, the intestinal microbiota might be causally related to the progression of insulin resistance and diabetes. FMT in metabolic syndrome has proven to be an intriguing method to study the role of the gut microbiota and open the way to new therapies by dissecting in whom insulin resistance is driven by microbiota. In this article we review the history of FMT, the present evidence on its role in the pathophysiology of metabolic syndrome and its efficacy, limitations and future prospects.

Original languageEnglish
Pages (from-to)253-267
Number of pages15
JournalGut Microbes
Volume8
Issue number3
DOIs
Publication statusPublished - 4 May 2017

Cite this